At a glance a summary of our key research activities are as follows:
As of June 2022 a total of approximately £15 million in funding has been committed for research, with individual funding in the range of £10,000 – £1,000,000+, and we are actively seeking new funding applications.
On this page is a summary of our current and completed projects with links to case studies, and a list of publications.
Current projects include:
Type of study: Interventional clinical trial
Description: Phase II, 1-year, open-label, pilot, study to examine the effects of sirolimus on colon polyp burden in Cowden syndrome. NCT04094675
Type of study: Clinical – natural history
Description: Retrospective analysis of data from a European cohort of PHTS patients to understand outcomes for those PHTS patients who develop cancer. The INSPECT study.
Description: Develop a UK PHTS patient registry to allow for the collection of high-quality clinical and epidemiological data to better understand PHTS.
Type of study: Clinical – tool development
Description: Develop a novel online tool for neurobehavioural evaluation of PHTS patients.
Type of study: Clinical – classification system development
Description: Validation of a PHTS specific classification system for vascular anomalies through radiologic/pathologic review of cases by international experts. This grant has been developed by the members of our Vascular anomalies Clinical Working Group.
Type of study: Clinical – better describe the neurological characteristics of PHTS
Description: Generation of a clinical picture of the neurological characteristics of PHTS to support a more sophisticated understanding of the disease phenotype, to develop clinical management guidelines and meaningful clinical trial endpoints.
Type of study: Clinical – guideline development
Description: This grant provides funds for a research assistant supporting the development of PHTS Management Guidelines by a multidisciplinary working group of PHTS experts and other key stakeholders.
Type of study: Pre-clinical – PHTS model
Description: Generate patient-derived iPSC lines to support future research on treatments.
Type of study: Clinical – natural history and translational
Description: Perform whole genome sequencing of a cohort of PHTS patients to assess how identify genetic variation contributes to phenotypic differences in people with PHTS.
Description: Repurposing studies focused on testing small molecule inhibitors of the PI3K pathway in pre-clinical models of PHTS vascular malformations, tissue overgrowth and oncology.
Description: Repurposing studies focused on testing small molecule inhibitors of the PI3K pathway in pre-clinical models of PHTS neurodevelopmental delay.
Type of study: Pre-clinical – PHTS model and translational
Description: Develop models of vascular malformation associated with PHTS to better understand their pathobiology and the contribution of various signalling molecules/pathways, and to test potential therapeutics.
Type of study: Pre-clinical – translational
Description: Assess the ability of potential therapeutics targeting the various nodes of the PI3K pathway to prevent cancer development in pre-clinical models of PHTS
Type of research: Basic research
Description: Characterise a series of PTEN antibodies to develop new research tools to better define and understand the biology and function of PTEN
Type of study: Pre-clinical - PHTS model
Description: Develop and characterise a novel pre-clinical model of PTEN loss in the brain for testing of potential therapeutics.
Type of study: Basic research
Description: Validation, using pre-clinical models of PHTS, of a novel target as a potential novel therapeutic strategy for PHTS.
Past projects include:
Type of study: Various
Description: PHTS registry and biorepository, Longitudinal study, Stem cells, Mouse Models and Eye Tracking in ASD.
Publications:
Yehia et al. PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Invest. 2019 Feb 1;129(2):452-464. doi: 10.1172/JCI121277
Yehia et al. PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation? Hum Mol Genet. 2020 Oct 20;29(R2):R150-R157. doi: 10.1093/hmg/ddaa127
Mighell et al. An Integrated Deep-Mutational-Scanning Approach Provides Clinical Insights on PTEN Genotype-Phenotype Relationships. Am J Hum Genet. 2020 Jun 4;106(6):818-829.doi: 10.1016/j.ajhg.2020.04.014
Yehia et al. Copy Number Variation and Clinical Outcomes in Patients With Germline PTEN Mutations. JAMA Netw Open. 2020 Jan 3;3(1):e1920415. doi: 10.1001/jamanetworkopen.2019.20415
Jia et al. Interplay Between Class II HLA Genotypes and the Microbiome and Immune Phenotypes in Individuals With PTEN Hamartoma Tumor Syndrome. JCO Precis Oncol. 2021 Feb 9;5:PO.20.00374. doi: 10.1200/PO.20.00374
Yehia et al. Distinct metabolic profiles associated with autism spectrum disorder versus cancer in individuals with germline PTEN mutations. NPJ Genom Med. 2022 Mar 3;7(1):16. doi: 10.1038/s41525-022-00289-x
Type of study: Basic research
Description: Characterisation of the biochemical properties of PTEN missense protein.
Genotype-Phenotype Study – Heriot Watt University, UK
Type of study: Basic research
Description: Dataset characterising biochemical properties of PTEN mutants associated with ASD or cancer.
Type of study: Clinical – natural history
Description: Assessing the prevalence of PTEN mutations in Turkish children. The prevalence of PTEN mutations in a cohort of 131 patients with ASD and macrocephaly was 3.8% (VUS included) or 2.29% (VUS omitted).
Publication: Kaymakcalan et al. Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. Mol Genet Genomic Med. 2021 Aug;9(8):e1739 doi: 10.1002/mgg3.1739
Type of study: Pre-clinical – translational
Description: The foundation has carried out a study with Imagen Therapeutics utilising their imaging technology to investigate the response of PTEN wild type and homozygous PTEN loss mouse embryonic fibroblasts to small molecule inhibitors targeting the PI3K signalling pathway. In addition to the PI3K pathway targeted agents, Imagen also tested their collection of oncology standard of care inhibitors and identified some unexpected differential sensitivity in the PTEN loss cells. These inhibitors have been incorporated into the ongoing studies in PHTS drug repurposing screens with our CRO partners.
Type of study: Clinical – natural history
Description: Survey done by Trinity Partners based on interviews of 22 patients/caregivers and 10 clinicians to understand the PHTS patient journey. The results emphasized the fact that each PHTS patient journey is unique but that there are certain manifestation combinations such as developmental delay combined with macrocephaly that leads to quicker diagnosis whereas patients with milder symptoms often go undiagnosed. The survey also identified challenges such as the uncertainty of cancer risk affecting the quality of life of patients. Other challenges identified included lack of physician awareness of PHTS and lack of patient-specific resources although Facebook groups were identified as the most helpful way for patients to find information and share their experience. Many patients and caregivers would be receptive to trying novel treatment options targeting PHTS.
Type of study: Translational medicine
Description: Cancer prevention with rapamycin in PHTS mouse model.
Type of study: Clinical – natural history
Description: Retrospective analysis of data from a European cohort of PHTS patients to refine the risk of cancer and the occurrence of other manifestations associated with PHTS.
Description: Phase I/II 6-month, randomized, double-blind placebo-controlled trial of everolimus in individuals, ages 5 to 45 years with a PTEN mutation, with safety and neurocognition as the primary endpoints. NCT02991807
Hardan et al. A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations. 2021 Contemporary Clinical Trials Communications, 21.doi: 10.1016/j.conctc.2021.100733
Srivastava et al (2022). A randomized controlled trial of Everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. 2022 Human Molecular Genetics.doi: 10.1093/HMG/DDAC111
Publications
Listed here are publications that are associated with the projects identified above, or for related activities in which PTEN Research (or its forerunner organisation) have been acknowledged.
